Annovis Bio raises $10 million to fund alzheimer's drug development

April 10, 2026 8:39 AM

Annovis Bio Inc. (NYSE: ANVS) completed a $10 million underwritten public offering to advance its investigational drug buntanetap for neurodegenerative ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found